Exploring the room for repurposed hydroxychloroquine to impede COVID-19: toxicities and multipronged combination approaches with pharmaceutical insights.
Identifieur interne : 000184 ( Main/Corpus ); précédent : 000183; suivant : 000185Exploring the room for repurposed hydroxychloroquine to impede COVID-19: toxicities and multipronged combination approaches with pharmaceutical insights.
Auteurs : Ankit Jain ; Shiv Kumar Prajapati ; Madhavi Tripathi ; Ashok M. Raichur ; Jagat R. KanwarSource :
- Expert review of clinical pharmacology [ 1751-2441 ] ; 2021.
Abstract
Introduction: SARS-CoV-2 has fatally affected the whole world with millions of deaths. Amidst the dilemma of a breakthrough in vaccine development, hydroxychloroquine (HCQ) was looked upon as a prospective repurposed candidate. It has confronted numerous controversies in the past few months as a chemoprophylactic and treatment option for COVID-19. Recently, it has been withdrawn by the World Health Organization for its use in an ongoing pandemic. However, its benefit/risk ratio regarding its use in COVID-19 disease remains poorly justified. An extensive literature search was done using Scopus, PubMed, Google Scholar, www.cdc.gov, www.fda.gov, and who.int.Areas covered: It is an attempt to unravel the toxicity vexations of HCQ along with the pharmaceutical perspectives in the current scenario. This will be followed by brief discussions on new advances in drug delivery approaches and computational modelling (PBPK and PD modelling) overtures. Multipronged combination approaches for enhanced synergism with antiviral and anti-inflammatory agents, and immuno-boosting effects, have also been discussed.Expert opinion: Harnessing the multipronged pharmaceutical perspectives will optimistically help the researchers, scientists, biotech, and pharmaceutical companies to bring new horizons in the safe and efficacious utilization of HCQ alone or in combination with remdesivir and immunomodulatory molecules like bovine lactoferrin in a fight against COVID-19. These different combinational therapies with free forms or nanomedicine based targeted approaches can act synergistically to boost host immunity and stop SARS-CoV-2 replication and invasion to impede the infection.
DOI: 10.1080/17512433.2021.1909473
PubMed: 33769888
Links to Exploration step
pubmed:33769888Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Exploring the room for repurposed hydroxychloroquine to impede COVID-19: toxicities and multipronged combination approaches with pharmaceutical insights.</title><author><name sortKey="Jain, Ankit" sort="Jain, Ankit" uniqKey="Jain A" first="Ankit" last="Jain">Ankit Jain</name><affiliation><nlm:affiliation>Department of Materials Engineering, Indian Institute of Science, Bangalore - 560012, Karnataka, India.</nlm:affiliation></affiliation></author><author><name sortKey="Prajapati, Shiv Kumar" sort="Prajapati, Shiv Kumar" uniqKey="Prajapati S" first="Shiv Kumar" last="Prajapati">Shiv Kumar Prajapati</name><affiliation><nlm:affiliation>Department of Pharmaceutical Sciences, Bhagyoday Tirth Pharmacy College, Sagar - 470002, Madhya Pradesh, India.</nlm:affiliation></affiliation></author><author><name sortKey="Tripathi, Madhavi" sort="Tripathi, Madhavi" uniqKey="Tripathi M" first="Madhavi" last="Tripathi">Madhavi Tripathi</name><affiliation><nlm:affiliation>Department of Materials Engineering, Indian Institute of Science, Bangalore - 560012, Karnataka, India.</nlm:affiliation></affiliation></author><author><name sortKey="Raichur, Ashok M" sort="Raichur, Ashok M" uniqKey="Raichur A" first="Ashok M" last="Raichur">Ashok M. Raichur</name><affiliation><nlm:affiliation>Department of Materials Engineering, Indian Institute of Science, Bangalore - 560012, Karnataka, India.</nlm:affiliation></affiliation></author><author><name sortKey="Kanwar, Jagat R" sort="Kanwar, Jagat R" uniqKey="Kanwar J" first="Jagat R" last="Kanwar">Jagat R. Kanwar</name><affiliation><nlm:affiliation>Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), Bilaspur, HP- - 174001, India.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:33769888</idno><idno type="pmid">33769888</idno><idno type="doi">10.1080/17512433.2021.1909473</idno><idno type="wicri:Area/Main/Corpus">000184</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000184</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Exploring the room for repurposed hydroxychloroquine to impede COVID-19: toxicities and multipronged combination approaches with pharmaceutical insights.</title><author><name sortKey="Jain, Ankit" sort="Jain, Ankit" uniqKey="Jain A" first="Ankit" last="Jain">Ankit Jain</name><affiliation><nlm:affiliation>Department of Materials Engineering, Indian Institute of Science, Bangalore - 560012, Karnataka, India.</nlm:affiliation></affiliation></author><author><name sortKey="Prajapati, Shiv Kumar" sort="Prajapati, Shiv Kumar" uniqKey="Prajapati S" first="Shiv Kumar" last="Prajapati">Shiv Kumar Prajapati</name><affiliation><nlm:affiliation>Department of Pharmaceutical Sciences, Bhagyoday Tirth Pharmacy College, Sagar - 470002, Madhya Pradesh, India.</nlm:affiliation></affiliation></author><author><name sortKey="Tripathi, Madhavi" sort="Tripathi, Madhavi" uniqKey="Tripathi M" first="Madhavi" last="Tripathi">Madhavi Tripathi</name><affiliation><nlm:affiliation>Department of Materials Engineering, Indian Institute of Science, Bangalore - 560012, Karnataka, India.</nlm:affiliation></affiliation></author><author><name sortKey="Raichur, Ashok M" sort="Raichur, Ashok M" uniqKey="Raichur A" first="Ashok M" last="Raichur">Ashok M. Raichur</name><affiliation><nlm:affiliation>Department of Materials Engineering, Indian Institute of Science, Bangalore - 560012, Karnataka, India.</nlm:affiliation></affiliation></author><author><name sortKey="Kanwar, Jagat R" sort="Kanwar, Jagat R" uniqKey="Kanwar J" first="Jagat R" last="Kanwar">Jagat R. Kanwar</name><affiliation><nlm:affiliation>Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), Bilaspur, HP- - 174001, India.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Expert review of clinical pharmacology</title><idno type="eISSN">1751-2441</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><b>Introduction</b>: SARS-CoV-2 has fatally affected the whole world with millions of deaths. Amidst the dilemma of a breakthrough in vaccine development, hydroxychloroquine (HCQ) was looked upon as a prospective repurposed candidate. It has confronted numerous controversies in the past few months as a chemoprophylactic and treatment option for COVID-19. Recently, it has been withdrawn by the World Health Organization for its use in an ongoing pandemic. However, its benefit/risk ratio regarding its use in COVID-19 disease remains poorly justified. An extensive literature search was done using Scopus, PubMed, Google Scholar, www.cdc.gov, www.fda.gov, and who.int.<b>Areas covered</b>: It is an attempt to unravel the toxicity vexations of HCQ along with the pharmaceutical perspectives in the current scenario. This will be followed by brief discussions on new advances in drug delivery approaches and computational modelling (PBPK and PD modelling) overtures. Multipronged combination approaches for enhanced synergism with antiviral and anti-inflammatory agents, and immuno-boosting effects, have also been discussed.<b>Expert opinion</b>: Harnessing the multipronged pharmaceutical perspectives will optimistically help the researchers, scientists, biotech, and pharmaceutical companies to bring new horizons in the safe and efficacious utilization of HCQ alone or in combination with remdesivir and immunomodulatory molecules like bovine lactoferrin in a fight against COVID-19. These different combinational therapies with free forms or nanomedicine based targeted approaches can act synergistically to boost host immunity and stop SARS-CoV-2 replication and invasion to impede the infection.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">33769888</PMID><DateRevised><Year>2021</Year><Month>03</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1751-2441</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2021</Year><Month>Mar</Month><Day>26</Day></PubDate></JournalIssue><Title>Expert review of clinical pharmacology</Title><ISOAbbreviation>Expert Rev Clin Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Exploring the room for repurposed hydroxychloroquine to impede COVID-19: toxicities and multipronged combination approaches with pharmaceutical insights.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1080/17512433.2021.1909473</ELocationID><Abstract><AbstractText><b>Introduction</b>: SARS-CoV-2 has fatally affected the whole world with millions of deaths. Amidst the dilemma of a breakthrough in vaccine development, hydroxychloroquine (HCQ) was looked upon as a prospective repurposed candidate. It has confronted numerous controversies in the past few months as a chemoprophylactic and treatment option for COVID-19. Recently, it has been withdrawn by the World Health Organization for its use in an ongoing pandemic. However, its benefit/risk ratio regarding its use in COVID-19 disease remains poorly justified. An extensive literature search was done using Scopus, PubMed, Google Scholar, www.cdc.gov, www.fda.gov, and who.int.<b>Areas covered</b>: It is an attempt to unravel the toxicity vexations of HCQ along with the pharmaceutical perspectives in the current scenario. This will be followed by brief discussions on new advances in drug delivery approaches and computational modelling (PBPK and PD modelling) overtures. Multipronged combination approaches for enhanced synergism with antiviral and anti-inflammatory agents, and immuno-boosting effects, have also been discussed.<b>Expert opinion</b>: Harnessing the multipronged pharmaceutical perspectives will optimistically help the researchers, scientists, biotech, and pharmaceutical companies to bring new horizons in the safe and efficacious utilization of HCQ alone or in combination with remdesivir and immunomodulatory molecules like bovine lactoferrin in a fight against COVID-19. These different combinational therapies with free forms or nanomedicine based targeted approaches can act synergistically to boost host immunity and stop SARS-CoV-2 replication and invasion to impede the infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Ankit</ForeName><Initials>A</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-8131-1860</Identifier><AffiliationInfo><Affiliation>Department of Materials Engineering, Indian Institute of Science, Bangalore - 560012, Karnataka, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prajapati</LastName><ForeName>Shiv Kumar</ForeName><Initials>SK</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-9089-579X</Identifier><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, Bhagyoday Tirth Pharmacy College, Sagar - 470002, Madhya Pradesh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tripathi</LastName><ForeName>Madhavi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Materials Engineering, Indian Institute of Science, Bangalore - 560012, Karnataka, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raichur</LastName><ForeName>Ashok M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Materials Engineering, Indian Institute of Science, Bangalore - 560012, Karnataka, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanwar</LastName><ForeName>Jagat R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), Bilaspur, HP- - 174001, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Clin Pharmacol</MedlineTA><NlmUniqueID>101278296</NlmUniqueID><ISSNLinking>1751-2433</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">angiotensin-converting enzyme-2</Keyword><Keyword MajorTopicYN="N">combinational therapy</Keyword><Keyword MajorTopicYN="N">drug delivery</Keyword><Keyword MajorTopicYN="N">hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">immunomodulation</Keyword><Keyword MajorTopicYN="N">pharmaceutical considerations</Keyword><Keyword MajorTopicYN="N">remdesivir</Keyword><Keyword MajorTopicYN="N">toxicity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>26</Day><Hour>17</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33769888</ArticleId><ArticleId IdType="doi">10.1080/17512433.2021.1909473</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000184 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000184 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:33769888
|texte= Exploring the room for repurposed hydroxychloroquine to impede COVID-19: toxicities and multipronged combination approaches with pharmaceutical insights.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:33769888" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |